Yüklüyor......
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are recommended for glycaemic management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP‐1RA, has recently been approved for clinical use, based on the results of the randomized, Phase 3a Peptide InnOvatioN for Early d...
Kaydedildi:
| Yayımlandı: | Diabetes Obes Metab |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Blackwell Publishing Ltd
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7384149/ https://ncbi.nlm.nih.gov/pubmed/32267058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14054 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|